المؤلفون: Shuaizhang Li (4876318), Andrew J. Li (11147897), Jameson Travers (7363991), Tuan Xu (338730), Srilatha Sakamuru (1911925), Carleen Klumpp-Thomas (3371171), Ruili Huang (480703), Menghang Xia (480707)

مصطلحات موضوعية: Pharmacology and Pharmaceutical Sciences not elsewhere classified, butyrylcholinesterase, BChE inhibitors, colorimetric BChE assay, qHTS, molecular docking

Relation: https://figshare.com/articles/journal_contribution/sj-pdf-1-jbx-10_1177_24725552211030897_Supplemental_material_for_Identification_of_Compounds_for_Butyrylcholinesterase_Inhibition/14998616

الاتاحة: https://doi.org/10.25384/sage.14998616.v1

المؤلفون: Jason M. Rohde (10531594), Surendra Karavadhi (6051887), Rajan Pragani (105058), Li Liu (75607), Yuhong Fang (3032253), Weihe Zhang (1332372), Andrew McIver (10531597), Hongchao Zheng (531059), Qingyang Liu (1508776), Mindy I. Davis (105040), Daniel J. Urban (9424971), Tobie D. Lee (4583152), Dorian M. Cheff (4583155), Melinda Hollingshead (107715), Mark J. Henderson (811537), Natalia J. Martinez (3090897), Kyle R. Brimacombe (1860301), Adam Yasgar (134148), Wei Zhao (14321), Carleen Klumpp-Thomas (3371171), Sam Michael (105053), Joseph Covey (10531600), William J. Moore (1464922), Gordon M. Stott (4583158), Zhuyin Li (105078), Anton Simeonov (85099), Ajit Jadhav (85100), Stephen Frye (2210458), Matthew D. Hall (316516), Min Shen (68726), Xiaodong Wang (66801), Samarjit Patnaik (1878463), Matthew B. Boxer (1860292)

مصطلحات موضوعية: Medicine, Cell Biology, Molecular Biology, Pharmacology, Biotechnology, Cancer, Hematology, Virology, Chemical Sciences not elsewhere classified, 48 h, tumoral concentrations, dose, myeloid leukemia, Cancer Neomorphic mutations, Pyridin, screening, SAR, mIDH 1-U mouse model, R 132C, Mutant Isocitrate Dehydrogenase 1, R 132H, malignancy, isocitrate dehydrogenase, glioma, isocitrate dehydrogenase 1, series, ivosidenib, chemistry campaign, Optimization, post

Relation: https://figshare.com/articles/journal_contribution/Discovery_and_Optimization_of_2_i_H_i_1_sup_2_sup_Pyridin-2-one_Inhibitors_of_Mutant_Isocitrate_Dehydrogenase_1_for_the_Treatment_of_Cancer/14378707

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00019.s002

المؤلفون: Jason M. Rohde (10531594), Surendra Karavadhi (6051887), Rajan Pragani (105058), Li Liu (75607), Yuhong Fang (3032253), Weihe Zhang (1332372), Andrew McIver (10531597), Hongchao Zheng (531059), Qingyang Liu (1508776), Mindy I. Davis (105040), Daniel J. Urban (9424971), Tobie D. Lee (4583152), Dorian M. Cheff (4583155), Melinda Hollingshead (107715), Mark J. Henderson (811537), Natalia J. Martinez (3090897), Kyle R. Brimacombe (1860301), Adam Yasgar (134148), Wei Zhao (14321), Carleen Klumpp-Thomas (3371171), Sam Michael (105053), Joseph Covey (10531600), William J. Moore (1464922), Gordon M. Stott (4583158), Zhuyin Li (105078), Anton Simeonov (85099), Ajit Jadhav (85100), Stephen Frye (2210458), Matthew D. Hall (316516), Min Shen (68726), Xiaodong Wang (66801), Samarjit Patnaik (1878463), Matthew B. Boxer (1860292)

مصطلحات موضوعية: Medicine, Cell Biology, Molecular Biology, Pharmacology, Biotechnology, Cancer, Hematology, Virology, Chemical Sciences not elsewhere classified, 48 h, tumoral concentrations, dose, myeloid leukemia, Cancer Neomorphic mutations, Pyridin, screening, SAR, mIDH 1-U mouse model, R 132C, Mutant Isocitrate Dehydrogenase 1, R 132H, malignancy, isocitrate dehydrogenase, glioma, isocitrate dehydrogenase 1, series, ivosidenib, chemistry campaign, Optimization, post

Relation: https://figshare.com/articles/dataset/Discovery_and_Optimization_of_2_i_H_i_1_sup_2_sup_Pyridin-2-one_Inhibitors_of_Mutant_Isocitrate_Dehydrogenase_1_for_the_Treatment_of_Cancer/14378704

الاتاحة: https://doi.org/10.1021/acs.jmedchem.1c00019.s001